Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
Revenue of Relmada Therapeutics, Inc. (RLMD)
Revenue in 2023 (TTM): $
According to Relmada Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Relmada Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $ | $4.91 M | $-98,791,746 | $-98,791,746 |
| 2022 | $ | $ | $-157,043,821 | $-157,043,823 | $-157,043,823 |
| 2021 | $ | $-1,258 | $-125,750,549 | $-125,751,809 | $-125,751,809 |
| 2020 | $ | $-3,752 | $-59,452,639 | $-59,456,394 | $-59,456,394 |
| 2019 | $ | $ | $-15,104,948 | $-15,005,198 | $-15,005,198 |
| 2018 | $ | $-4,870 | $-16,552,152 | $-17,318,060 | $-17,318,060 |
| 2017 | $ | $-2,627 | $-6,914,848 | $-8,960,852 | $-8,960,852 |
| 2016 | $ | $-85,271 | $-6,922,544 | $-6,286,521 | $-6,286,521 |
| 2015 | $ | $-54,819 | $-16,030,484 | $-2,974,691 | $-2,974,691 |
| 2014 | $ | $-9,256 | $-17,090,024 | $-20,803,596 | $-20,803,596 |
| 2013 | $5.13 K | $1.09 K | $-45,015 | $-45,015 | $-45,015 |
| 2012 | $7.94 K | $2.14 K | $-11,675 | $-12,052 | $-12,052 |